Cargando…
Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
An increasing number of myocarditis/pericarditis incidences has been reported after coronavirus disease-19 (COVID-19) vaccination in adolescents and young adults. This study was designed to investigate the incidence rate of—and risk for—myocarditis and pericarditis following COVID-19 vaccination in...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624452/ https://www.ncbi.nlm.nih.gov/pubmed/34834458 http://dx.doi.org/10.3390/jpm11111106 |
_version_ | 1784606177303199744 |
---|---|
author | Li, Minghui Yuan, Jing Lv, Gang Brown, Jacob Jiang, Xiangxiang Lu, Zhiqiang Kevin |
author_facet | Li, Minghui Yuan, Jing Lv, Gang Brown, Jacob Jiang, Xiangxiang Lu, Zhiqiang Kevin |
author_sort | Li, Minghui |
collection | PubMed |
description | An increasing number of myocarditis/pericarditis incidences has been reported after coronavirus disease-19 (COVID-19) vaccination in adolescents and young adults. This study was designed to investigate the incidence rate of—and risk for—myocarditis and pericarditis following COVID-19 vaccination in the United States according to age and vaccine type. This study used the Vaccine Adverse Events Reporting System (VAERS) from 11 December 2020 to 13 August 2021. A population-based data mining approach was performed based on the reporting odds ratio (ROR). Adverse events of myocarditis and pericarditis following COVID-19 vaccination were rare, with an incidence rate of 5.98 (95% CI = 5.73–6.24) cases per million doses administered. The incidence rate was higher in adolescents and after the administration of the second dose of messenger RNA (mRNA) vaccines. Overall, two mRNA vaccines were significantly associated with increased risks for myocarditis/pericarditis (mRNA-1273 (Moderna): ROR = 2.91, 95% CI = 2.21–3.83; BNT162b2 (Pfizer–BioNTech): ROR = 5.37, 95% CI = 4.10–7.04) compared to all other vaccines from VAERS. The viral vector vaccine of Ad26.COV2.S (Janssen) was not associated with signals of myocarditis/pericarditis (ROR = 1.39; 95% CI = 0.99–1.97). This study found increased risks for myocarditis/pericarditis following mRNA COVID-19 vaccines. For patients at high risk for myocarditis/pericarditis or with myocardial injuries, the viral vector vaccine may be an alternative for consideration. |
format | Online Article Text |
id | pubmed-8624452 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86244522021-11-27 Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types Li, Minghui Yuan, Jing Lv, Gang Brown, Jacob Jiang, Xiangxiang Lu, Zhiqiang Kevin J Pers Med Article An increasing number of myocarditis/pericarditis incidences has been reported after coronavirus disease-19 (COVID-19) vaccination in adolescents and young adults. This study was designed to investigate the incidence rate of—and risk for—myocarditis and pericarditis following COVID-19 vaccination in the United States according to age and vaccine type. This study used the Vaccine Adverse Events Reporting System (VAERS) from 11 December 2020 to 13 August 2021. A population-based data mining approach was performed based on the reporting odds ratio (ROR). Adverse events of myocarditis and pericarditis following COVID-19 vaccination were rare, with an incidence rate of 5.98 (95% CI = 5.73–6.24) cases per million doses administered. The incidence rate was higher in adolescents and after the administration of the second dose of messenger RNA (mRNA) vaccines. Overall, two mRNA vaccines were significantly associated with increased risks for myocarditis/pericarditis (mRNA-1273 (Moderna): ROR = 2.91, 95% CI = 2.21–3.83; BNT162b2 (Pfizer–BioNTech): ROR = 5.37, 95% CI = 4.10–7.04) compared to all other vaccines from VAERS. The viral vector vaccine of Ad26.COV2.S (Janssen) was not associated with signals of myocarditis/pericarditis (ROR = 1.39; 95% CI = 0.99–1.97). This study found increased risks for myocarditis/pericarditis following mRNA COVID-19 vaccines. For patients at high risk for myocarditis/pericarditis or with myocardial injuries, the viral vector vaccine may be an alternative for consideration. MDPI 2021-10-28 /pmc/articles/PMC8624452/ /pubmed/34834458 http://dx.doi.org/10.3390/jpm11111106 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Li, Minghui Yuan, Jing Lv, Gang Brown, Jacob Jiang, Xiangxiang Lu, Zhiqiang Kevin Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types |
title | Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types |
title_full | Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types |
title_fullStr | Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types |
title_full_unstemmed | Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types |
title_short | Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types |
title_sort | myocarditis and pericarditis following covid-19 vaccination: inequalities in age and vaccine types |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624452/ https://www.ncbi.nlm.nih.gov/pubmed/34834458 http://dx.doi.org/10.3390/jpm11111106 |
work_keys_str_mv | AT liminghui myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes AT yuanjing myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes AT lvgang myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes AT brownjacob myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes AT jiangxiangxiang myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes AT luzhiqiangkevin myocarditisandpericarditisfollowingcovid19vaccinationinequalitiesinageandvaccinetypes |